WO2004060339A1 - Compositions de proteines de ble polymerisees et derives d'ethanolamine - Google Patents

Compositions de proteines de ble polymerisees et derives d'ethanolamine Download PDF

Info

Publication number
WO2004060339A1
WO2004060339A1 PCT/EP2004/000141 EP2004000141W WO2004060339A1 WO 2004060339 A1 WO2004060339 A1 WO 2004060339A1 EP 2004000141 W EP2004000141 W EP 2004000141W WO 2004060339 A1 WO2004060339 A1 WO 2004060339A1
Authority
WO
WIPO (PCT)
Prior art keywords
polymerized
composition
skin
ethanolamine
proteins
Prior art date
Application number
PCT/EP2004/000141
Other languages
English (en)
Inventor
Muriel Morelli
Magali Jousselin
Original Assignee
Johnson & Johnson Consumer France S.A.S.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson & Johnson Consumer France S.A.S. filed Critical Johnson & Johnson Consumer France S.A.S.
Priority to EP04700259A priority Critical patent/EP1581179A1/fr
Priority to BR0406630-8A priority patent/BRPI0406630A/pt
Priority to CA002512249A priority patent/CA2512249A1/fr
Publication of WO2004060339A1 publication Critical patent/WO2004060339A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/41—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/645—Proteins of vegetable origin; Derivatives or degradation products thereof

Definitions

  • compositions comprising an ethanolamine derivative and a polymerized wheat protein. It further relates to the use of such compositions in topical formulations, in particular in anti-aging formulations. The invention further relates to the use of such compositions to combat the effects of skin aging.
  • the appearance and condition of the skin may be degraded through external factors such as sunlight, exposure to wind and to cool and dry air, air pollutants, smoking, as well as internal factors such as dermatological diseases, age-related hormonal changes, or the normal aging process.
  • Cosmetic products have been developed that have proved out to be more or less effective in combating the effects of skin aging.
  • Particular such products are those containing vitamins or vitamin derivatives, in particular vitamin A or its derivatives (retinoids), vitamin C, alpha-hydroxy acids or plant extracts. These products, when applied regularly during longer periods of time, have been shown to reduce the number of wrinkles and fine wrinkles.
  • a particular pathway used in the treatment of the effects of skin aging is by stimulation of dermal human fibroblasts and collagen formation. Agents possessing these properties for example are L-ascorbic acid and in particular retinol.
  • ethanolamine derivatives Other agents that have been described as useful to treat the effects of skin aging are the ethanolamine derivatives.
  • US 5,554,647 describes a method of treating aging skin and subcutaneous muscles comprising the use of an acetylcholine precursor such as dimethylaminoethanol (DMAE) in an amount effective to produce increased muscle tone.
  • DMAE dimethylaminoethanol
  • US 5,643,586 describes the topical treatment of subcutaneous muscle and overlying cutaneous tissue by applying a composition comprising a catecholamine precursor which in particular is tyrosine, phenylalanine or a mixture thereof preferably in combination with an acetylcholine precursor such as dimethylaminoethanol.
  • a catecholamine precursor which in particular is tyrosine, phenylalanine or a mixture thereof preferably in combination with an acetylcholine precursor such as dimethylaminoethanol.
  • EP-A-1219288 relates to a topical composition for the treatment of skin, in particular to improve skin firmness, comprising an effective amount of an ethanolamine salt which has a mixture of anionic counterions derived from at least two pharmaceutically acceptable acids and esters thereof; and a cosmetically acceptable carrier.
  • an ethanolamine salt which has a mixture of anionic counterions derived from at least two pharmaceutically acceptable acids and esters thereof; and a cosmetically acceptable carrier.
  • compositions and formulations according to the present invention which will be described hereinafter in more detail, are aimed at being effective tools in combating the effects of skin aging.
  • the present invention is directed to a composition comprising at least one ethanolamine derivative of formula (I), or a skin acceptable salt thereof:
  • R 1 and R 2 independently represent hydrogen, C 3 - 6 cycloalkyl or -e alkyl, optionally substituted with hydroxy, methoxy, oxo or formyl.
  • R 1 and R 2 independently represent C ⁇ - 4 alkyl.
  • DMAE dimethylaminoethanol
  • the polymerized wheat protein is obtainable from hydrolyzed wheat protein hydrolysates, which are polymerized by using an appropriate multifunctional polymerizing agent.
  • the invention further is concerned with a topical formulation comprising a composition as defined herein and a cosmetically-acceptable or dermatologically- acceptable topical carrier.
  • a topical formulation comprising a composition as defined herein and a cosmetically-acceptable or dermatologically- acceptable topical carrier.
  • the latter may comprise one or more further ingredients.
  • the topical formulation can be for dermatological use but is in particular for cosmetic use.
  • the invention provides the use of a composition as defined herein for manufacturing a topical or in particular a cosmetic formulation.
  • the topical or cosmetic formulations are useful for combating or treating the effects of skin aging.
  • the invention provides the use, and more specifically the cosmetic use, of a composition as defined herein, or of a topical formulation as defined herein, for combating or treating the effects associated with the aging of skin.
  • the invention concerns a method, and in particular a cosmetic method, of combating or treating the effects of skin aging, which method or cosmetic method comprises applying to the affected skin area an amount of a composition or of a topical formulation as defined herein, said amount being effective to treat said effects of skin aging.
  • Still another aspect of this invention comprises a cosmetic method for the improvement of the external appearance of an individual, said method comprising applying an effective amount of a composition or a topical composition as defined herein to affected skin areas.
  • any percentage is weight-by-weight (w/w) relative to the total weight of the composition or of the formulation.
  • 'effective amount means an amount of composition or formulation sufficient to significantly induce a positive modification in the condition to be regulated or treated, but low enough to avoid serious side effects.
  • the effective amount of the composition or formulation will vary with the particular condition being treated, the age and physical condition of the end user, the severity of the condition being treated/prevented, the duration of the treatment, the nature of concurrent therapy, the specific composition or formulation employed, the particular cosmetically- acceptable topical carrier utilized, and like factors.
  • compositions of this invention comprise polymerized wheat proteins of high molecular weight.
  • These polymerized wheat proteins can be prepared by a process comprising the following steps : 1) solubilizing in an aqueous phase a material which is rich in wheat proteins;
  • the source of wheat proteins used in the first step can be any material derived from wheat that is sufficiently rich in wheat proteins. Suitable materials are, for example, wheat flour, wheat extracts, wheat gluten and the like.
  • the process preferably is conducted under following circumstances.
  • the starting wheat protein rich material is solubilized at a concentration of 50 g/1 to 500 g/1.
  • the hydrolysis is carried out preferably in acid pH, preferably at a pH level in the range between 4 and 7 and at a temperature between 40°C and 80°C.
  • the enzymes that can be used in the hydrolysis step are proteases of the following type: endopro teases, exoproteases, exopeptidases, proteasepeptidases, aminomeptidases or carbopeptidases, or a mixture of these enzymes.
  • the enzymes are inactivated, for example by increasing the temperature of the reaction mixture to a temperature between 50°C and 80°C.
  • the level of hydrolysis is selected such that the percentage of hydrolysed wheat protein in fractions F2 and F3 is between about 70 : 60 to about 50 : 40 and in particular is about 50 : 50 (+/- 5%), with no or almost no hydrolysed protein in fraction FI (preferably less than about 5%), wherein FI, F2 and F3 are as defined hereinafter.
  • the polymerizing agent preferably is a multifunctional polymerizing agent selected from the group of polymerization initiators comprising polychlorides of acids, acid polyanhydrides, polyisocyanates, polythioisocyanates.
  • the polymerization step is preferably carried out with a level of polymerization agent between 10 g 1 and 100 g/1, selected so as to obtain a level of polymerized proteins that is higher than 30%. Preferably about one equivalent of the polymerizing agent is used.
  • the separation of the polymerized wheat proteins can be carried out by filtration, decantation, centrifugation and concentration.
  • an amount of dry material when obtained by heating the isolated polymerized protein at about 105°C until a constant weight is reached, of about 5 g/1 to about 500 g/1, preferably of about 50 g/1 to about 250 g/1;
  • a pH measured potentiometrically at room temperature, of about 2 to about 10, preferably of about 4 to about 10, more preferably of about 7 to about 8;
  • the percentage of proteins in fraction FI is from about 15% to about 35%, in particular from about 20% to about 25%.
  • the percentage of proteins in fraction F2 is from about 15% to about 45%, in particular from about 20% to about 40%, of particular interest are polymerized wheat proteins wherein the percentage of proteins in fraction FI is about 45% (+/- 5%), in fraction F2 is about 30% (+/- 5%) and in fraction F3 is about 25% (+/- 5%).
  • a particularly preferred polymerized wheat protein is available under the trade name 'Polymere de Ble' from the company Silab (France).
  • Figure 1 represents a chromotographical profile of the polymerized wheat protein 'Polymere de Ble' .
  • compositions of the present invention contain an ethanolamine of formula (I) as defined above.
  • C 3 - 6 cycloalkyl refers to a cyclic cycloalkyl radical having from 3 to 6 carbon atoms and that preferably is saturated such as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
  • C ⁇ - 6 alkyl refers to straight and branch chained hydrocarbon radicals which preferably are saturated and have from 1 to 6 carbon atoms such as, for example, methyl, ethyl, n.propyl, iso-propyl, n.butyl, iso-butyl, t.butyl, n.
  • C ⁇ - 4 alkyl refers to the same group of radicals having 1 to 4 carbon atoms.
  • a particularly preferred ethanolamine of formula (I) is DMAE (deanol).
  • the ethanolamines of formula (I) can be prepared according to art-known procedures, e.g. by alkylating ethanolamine.
  • the ethanolamines of formula (I) can be used in their basic form or can be used as appropriate topically acceptable salts, the latter referring to acid-addition salt forms that are biologically acceptable for the skin and/or mucous membranes.
  • Biologically acceptable in particular refers to lack of toxicity and of adverse effects such as irritation, allergic reactions and the like.
  • Suitable topically acceptable salts are those that are obtained by treating the base form of the ethanolamine of formula (I) with an appropriate acid.
  • Suitable acids for use in the preparation of the ethanolamine salts according to the invention include any inorganic or, which is preferred, organic acid known to be useful in skin care compositions. These include acids such as, for example, inorganic acids such as hydrohalic acids, e.g.
  • hydrochloric or hydrobromic acid boric, sulfuric, nitric, phosphoric and the like acids; or organic acids such as, for example, acetic, propanoic, hydroxyacetic (or glycolic), lactic, pyruvic, oxalic, malonic, succinic, maleic, fumaric, malic, tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, p- toluenesulfonic, cyclamic, salicylic, p-aminosalicylic, ascorbic and the like acids.
  • organic acids such as, for example, acetic, propanoic, hydroxyacetic (or glycolic), lactic, pyruvic, oxalic, malonic, succinic, maleic, fumaric, malic, tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, p- to
  • At least one of the acids is an alpha hydroxy acid, such as taught for example in U.S. Patent No. 5,856,357, the disclosure of which is hereby incorporated by reference.
  • Particularly preferred is a mixture of at least two of glycolic acid, malic acid and citric acids.
  • the acid is a combination of glycolic acid and either malic or citric acid.
  • pH stability is a particular concern, e.g., long term storage
  • a particularly preferred embodiment is when the acid is a mixture of citric and glycolic acid.
  • the ratio of malic or citric acid to glycolic acid ranges from about 1:1 to about 1:5, more preferably, from about 1:1 to about 1:3.
  • Tyrosine Another compound, which is advantageously present in the compositions or formulations of this invention is tyrosine.
  • Tyrosine may be present in the compositions or formulations of this invention in the amount of from about 0.01 to about 5%, more preferably from about 0.04 to about 3% by weight and most preferably about 0.5% by weight, based on the total composition or formulation.
  • compositions of the present invention are prepared by mixing at least one polymerized wheat protein with at least one ethanolamine of formula (I) or a salt form thereof, and if desired by adding further ingredients.
  • the polymerized wheat proteins preferably are formulated in an aqueous medium, optionally in the presence of suitable preservatives.
  • the compositions of the present invention therefore are mostly of aqueous nature. They may be prepared by adding the aqueous formulations of polymerized wheat proteins to the ethanolamine of formula (I), or its salt form, or vice versa.
  • the w/w ratio of the ethanolamine (I) to the polymerized wheat proteins may vary but in particular is in the range of about 50 : 1 to about 1 : 1, in particular of about 20 : 1 to about 2 : 1, preferably from about 15 : 1 to about 5 : 1, more preferably the w/w ratio is about 8 : 1 to 7 : 1 (ethanolamine : wheat proteins).
  • the quantity of ethanolamine is that of ethanolamine free base, meaning that if salts are used the ratios need to be recalculated accordingly.
  • the quantity of polymerized wheat protein referred to in this paragraph is that of dry material.
  • Topical formulations comprise dermatological formulations (or topical pharmaceutical formulations), and cosmetic formulations.
  • Said topical formulations may further contain other ingredients or additives used in dermatological or in cosmetic formulations, including other active ingredients.
  • further ingredients or additives are surfactants, emulsifiers, consistency factors, conditioners, emollients, skin caring ingredients, moisturizers, thickeners, lubricants, fillers, binding agents, anti- oxidants, preservatives, active ingredients, in particular dermatologically active ingredients, fragrances and the like.
  • Active ingredients as mentioned herein comprise, for example, anti-inflammatories, anti-bacterials, anti-fungals and the like agents. Of particular interest are any active ingredients suited for topical applications.
  • the topical formulations according to the invention can further include one or more of a variety of optional ingredients, such as coloring agents, opacifying agents and the like.
  • the ethanolamine and more specifically dimehylethanolamine may be used in the formulations for topical application at concentrations from about 0.01% to about 10%, preferably from about 0.1% to about 5%, more preferably from about 0.5% to about 5%.
  • the total amount of polymerized wheat proteins should be used in the formulations for topical application at concentrations which may vary between about 0.01 % to about 2%, preferably from about 0.05% to about 1%, more preferably from about 0.1% to about 0.5%. As used in this paragraph, the percentages of polymerized wheat proteins refer to dry material.
  • the formulations according to the present invention can be prepared by adding the appropriate ingredients to a composition of the invention, or vice versa by adding the composition to an appropriate cosmetic or dermatological formulation base. It is also possible to mix all the ingredients individually, i.e. without making a separate composition as defined herein.
  • the topical formulations according to the invention may be in the form of a solution, a hydrophilic lotion, an ointment, a cream or a gel.
  • the formulations may also be, for example, in the form of oil-in-water, water-in-oil or multiple emulsions, foaming products or in liposome form.
  • an oil phase containing the oil-soluble components
  • the first aqueous phase is made containing one or more suitable emulsifiers.
  • the oil phase is made and added to the first phase while building an emulsion.
  • the second aqueous phase is added.
  • the first or oil phase contains solid or semi-solid components, it is recommendable to heat the phase or phases and to conduct the emulsifying process at elevated temperature.
  • the topical formulations according to the invention can further include one or more of a variety of additional ingredients commonly found in skin care compositions, such as for example, emollients, skin conditioning agents, emulsifying agents, humectants, preservatives, antioxidants, active ingredients, perfumes, chelating agents, dyes, opacifying agents, etc., provided that they are physically and chemically compatible with the other components of the composition.
  • additional ingredients commonly found in skin care compositions, such as for example, emollients, skin conditioning agents, emulsifying agents, humectants, preservatives, antioxidants, active ingredients, perfumes, chelating agents, dyes, opacifying agents, etc.
  • vitamin A and vitamin A derivatives including but not restricted to retinol, retinyl palmitate, retinoic acid, retinal, and retinyl propionate.
  • active agents examples include anti-microbials, e.g. anti-bacterials and antifungals, anti-inflammatory agents, anti-irritating compounds, anti-itching agents, moisturising agents, skin caring ingredients, plant extracts, vitamins, and the like. Also included are sunscreen actives, which may be inorganic or organic in nature.
  • the preservative is present in an amount ranging from about 0.5 to about 2.0, preferably about 1.0 to about 1.5, weight percent based on the total composition.
  • the preservative is a mixture of from about 0.2 to about 0.5 weight percent methylparaben, from about 0.2 to about 5.0 weight percent propylparaben and from about 0.05 to about 0.10 weight percent butylparaben.
  • antioxidants should be present in the compositions or formulations according to the invention.
  • Suitable antioxidants include butylated hydroxy toluene (BHT), ascorbyl palmitate, butylated hydroanisole (BHA), phenyl- ⁇ -naphthylamine, hydroquinone, propyl gallate, nordihydroquiaretic acid, vitamin E or derivatives of vitamin E, vitamin C and derivatives thereof, calcium pantothenic, green tea extracts and mixed polyphenols, and mixtures thereof of the above.
  • BHT butylated hydroxy toluene
  • BHA butylated hydroanisole
  • phenyl- ⁇ -naphthylamine hydroquinone
  • propyl gallate nordihydroquiaretic acid
  • vitamin E or derivatives of vitamin E vitamin C and derivatives thereof
  • calcium pantothenic, green tea extracts and mixed polyphenols and mixtures thereof of the above.
  • the antioxidant can be present in an amount ranging from about 0.02 to about
  • Emollients which can be included in the compositions or formulations of the invention function by their ability to remain on the skin surface or in the stratum corneum to act as lubricants, to reduce flaking, and to improve the skin appearance.
  • Typical emollients include fatty esters, fatty alcohols, mineral oil, polyether siloxane copolymers and the like.
  • emollients include, but are not limited to, polypropylene glycol ("PPG")-15 stearyl ether, PPG-10 cetyl ether, steareth-10, olefh-8, PPG-4 lauryl ether, vitamin E acetate, PEG-7 glyceryl cocoate, lanolin, cetyl alcohol, octyl hydroxystearate, dimethicone, and combinations thereof. Cetyl alcohol, octyl hydroxystearate, dimethicone, and combinations thereof are preferred.
  • the emollient can be present in an amount from about 0.01 to about 5, preferably from about 1 to about 4 percent by weight based on the total composition.
  • Polyhydric alcohols can be utilized as humectants in the compositions or formulations of the invention.
  • the humectants aid in increasing the effectiveness of the emollient, reduce scaling, stimulate removal of built-up scale and improve skin feel.
  • Suitable polyhydric alcohols include, but are not limited to, glycerol (also known as glycerine), polyalkylene glycols, alkylene polyols and their derivatives, including butylene glycol, propylene glycol, dipropylene glycol, polypropylene glycol, polyethylene glycol and derivatives thereof, sorbitol, hydroxypropyl sorbitol, hexylene glycol, 1,3-dibutylene glycol, 1,2,6,-hexanetriol, ethoxylated glycerol, propoxylated glycerol and mixtures thereof.
  • Glycerine is preferred.
  • the humectant is present in an amount from about 0.1 to about 5, preferably
  • compositions and topical formulations subject of the present invention are useful to combat or to treat the effects of skin aging.
  • the effects of skin aging comprise those associated with the aging of the skin such as the appearance of fine lines, fine wrinkling, wrinkling, loss of skin firmness, skin tightening and suppleness.
  • the compositions and formulations of the present invention additionally act beneficially on the mechanical properties of the epidermis, stimulate the proliferation of dermal cells and in particular the proliferation of fibroblasts, stimulate of collagen synthesis, have a positive effect on cell metabolism and on extracellular matrix synthesis in dermal fibroblasts. They moreover have a firming and tightening effect, provide a more youthful and smooth aspect of the skin, and have a positive effect on its general appearance, in particular of facial skin.
  • ethanolamine derivatives and in particular DMAE are known to have skin-lifting and skin tightening effects and therefore improve the appearance of the skin.
  • the polymerized wheat protein and the ethanolamines of formula (I) act synergistically in their skin-lifting capability and therefore the compositions and formulations of the invention possess improved lifting capability. Moreover, quite unexpectedly it has been found that when using the compositions and formulations of the invention, the skin-lifting and skin-tightening effects are observed immediately and although the effect is immediate, it remains for a long period of time.
  • the ingredients are mixed in ingredient groups as listed above (each group being separated by a blanc in the above table).
  • the polymerized wheat protein is used dissolved in a small quantity of water together with the Paraben mixture. Subsequently the groups are mixed together to the end group.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des compositions comprenant un dérivé d'éthanolamine et une protéine de blé polymérisée. L'invention concerne, de plus, l'utilisation desdites compositions dans des formulations topiques, en particulier dans des formulations anti-âge. L'invention concerne, en outre, l'utilisation desdites compositions pour combattre les effets du vieillissement de la peau.
PCT/EP2004/000141 2003-01-06 2004-01-06 Compositions de proteines de ble polymerisees et derives d'ethanolamine WO2004060339A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP04700259A EP1581179A1 (fr) 2003-01-06 2004-01-06 Compositions de proteines de ble polymerisees et derives d'ethanolamine
BR0406630-8A BRPI0406630A (pt) 2003-01-06 2004-01-06 Composições de proteìnas de trigo polimerizadas e derivados de etanol amina
CA002512249A CA2512249A1 (fr) 2003-01-06 2004-01-06 Compositions de proteines de ble polymerisees et derives d'ethanolamine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03290026 2003-01-06
EP03290026.8 2003-01-06

Publications (1)

Publication Number Publication Date
WO2004060339A1 true WO2004060339A1 (fr) 2004-07-22

Family

ID=32695660

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/000141 WO2004060339A1 (fr) 2003-01-06 2004-01-06 Compositions de proteines de ble polymerisees et derives d'ethanolamine

Country Status (4)

Country Link
EP (1) EP1581179A1 (fr)
BR (1) BRPI0406630A (fr)
CA (1) CA2512249A1 (fr)
WO (1) WO2004060339A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1875895A1 (fr) 2006-07-07 2008-01-09 Johnson & Johnson Consumer France SAS Compositions à viscosité augmentée comprenant des électrolytes

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554647A (en) * 1989-10-12 1996-09-10 Perricone; Nicholas V. Method and compositions for treatment and/or prevention of skin damage and aging
WO1999042082A1 (fr) * 1998-02-23 1999-08-26 Pierre Fabre Dermo-Cosmetique Composition cosmetique comprenant des oligo-elements provenant d'eaux minerales et chelates par des hydrolysats de proteines vegetales
WO2001037799A1 (fr) * 1999-11-26 2001-05-31 Lvmh Recherche Extrait d'ajuga turkestanica et ses applications cosmetiques
EP1219288A2 (fr) * 2000-12-21 2002-07-03 Johnson & Johnson Consumer Companies, Inc. Composition pour traitement de la peau

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554647A (en) * 1989-10-12 1996-09-10 Perricone; Nicholas V. Method and compositions for treatment and/or prevention of skin damage and aging
WO1999042082A1 (fr) * 1998-02-23 1999-08-26 Pierre Fabre Dermo-Cosmetique Composition cosmetique comprenant des oligo-elements provenant d'eaux minerales et chelates par des hydrolysats de proteines vegetales
WO2001037799A1 (fr) * 1999-11-26 2001-05-31 Lvmh Recherche Extrait d'ajuga turkestanica et ses applications cosmetiques
EP1219288A2 (fr) * 2000-12-21 2002-07-03 Johnson & Johnson Consumer Companies, Inc. Composition pour traitement de la peau

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1875895A1 (fr) 2006-07-07 2008-01-09 Johnson & Johnson Consumer France SAS Compositions à viscosité augmentée comprenant des électrolytes

Also Published As

Publication number Publication date
BRPI0406630A (pt) 2005-12-06
EP1581179A1 (fr) 2005-10-05
CA2512249A1 (fr) 2004-07-22

Similar Documents

Publication Publication Date Title
EP1448162B1 (fr) Compositions comprenant un derive d'ethanolamine et sels metalliques organiques
EP1216696B1 (fr) Méthode pour réduire l'apparition de cercles sombres sous les yeux
US20050053563A1 (en) Stable compositions containing ethanolamine derivatives and glucosides
US20110065794A1 (en) Wrinkle-preventing and improving composition
KR20000028982A (ko) 하나 이상의 뽕나무 추출물, 하나 이상의 골무꽃 추출물및 하나 이상의 살리실산 유도체를 함유하는 화장용및/또는 피부용 조성물
US20030095991A1 (en) Treatment for skin
EP1551364B1 (fr) Preparations epaississantes comprenant de la gomme de sclerote et un copolymere
AU2004290893A1 (en) Compositions comprising soy products and dioic acids
JP2003012486A (ja) 皮膚外用剤
JP3278138B2 (ja) 皮膚外用剤
JPH10212225A (ja) 抗シワ剤
WO2004060339A1 (fr) Compositions de proteines de ble polymerisees et derives d'ethanolamine
JP2001131031A (ja) 頭皮頭髪用組成物
JP3023543B2 (ja) チロシナーゼ活性阻害剤及び化粧料
JP3382146B2 (ja) 皮膚外用剤
JPH0532537A (ja) 皮膚化粧料
KR20010050016A (ko) 외용 조성물
WO2004096167A1 (fr) Composition renfermant des derives d'ethanolamine et de l'acide citrique
AU2006201889A1 (en) Treatment for skin
WO2003053327A2 (fr) Compositions contenant un retinoide et un extrait de malt
JPH11199429A (ja) 皮膚外用剤
JPH10101665A (ja) スチルベン骨格を有する化合物、チロシナーゼ活性阻害剤及び化粧料

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004700259

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2512249

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2004700259

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0406630

Country of ref document: BR